Page
%P
-
Article
Open AccessFOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respo...